NIH PAR · NCATS · UG3, UH3
PAR-25-296: Limited Competition: Clinical and Translational Science Award (CTSA) Program: Collaborative and Innovative Acceleration Award (UG3/UH3 Clinical Trial Optional)
Reviewed by Dr. Meng ZhaoLast reviewed October 16, 2026Data refreshed October 16, 2026Editorial standards
The CTSA Collaborative and Innovative Acceleration Award (CCIA) aims to accelerate the pace of translational research by supporting the collaborative development, dissemination, and sustainable implementation of innovative solutions across the CTSA Program Consortium and beyond. This Notice of Funding Opportunity (NOFO) invites investigator-initiated applications to develop, demonstrate, and disseminate innovative new approaches, technologies, resources, or models that increase the impact of research across diseases, transform the field of translational science, and bring more treatments for all people more quickly.
- NOFO number
- PAR-25-296
- Type
- PAR
- Activity code
- UG3UH3
- Primary institute
- NCATS · National Center for Advancing Translational Sciences
- Clinical trials
- Optional
- Posted
- Dec 11, 2024
- Opens
- Jan 18, 2025
- Expires
- Oct 20, 2027
PAR-25-296 due dates
4 application due dates remain before the NOFO expires. Dates marked * are NIH standard due dates. Check the related notices below for changes NIH made after posting.
| Application Due Date(s) | Renewal / Resubmission / Revision (as allowed) | AIDS - New/Renewal/Resubmission/Revision, as allowed | Scientific Merit Review | Advisory Council Review | Earliest Start Date |
|---|---|---|---|---|---|
| February 19, 2025 | February 19, 2025 | Not Applicable | June 2025 | October 2025 | December 2025 |
| June 16, 2025 | June 16, 2025 | Not Applicable | October 2025 | January 2026 | April 2026 |
| October 17, 2025 | October 17, 2025 | Not Applicable | February 2026 | May 2026 | July 2026 |
| February 18, 2026 | February 18, 2026 | Not Applicable | June 2026 | October 2026 | December 2026 |
| June 15, 2026 | June 15, 2026 | Not Applicable | October 2026 | January 2027 | April 2027 |
| October 19, 2026 | October 19, 2026 | Not Applicable | February 2027 | May 2027 | July 2027 |
| February 17, 2027 | February 17, 2027 | Not Applicable | June 2027 | October 2027 | December 2027 |
| June 15, 2027 | June 15, 2027 | Not Applicable | October 2027 | January 2028 | April 2028 |
| October 19, 2027 | October 19, 2027 | Not Applicable | February 2028 | May 2028 | July 2028 |
Projects funded under PAR-25-296
NIH RePORTER lists 3 projects funded under PAR-25-296 in FY2022–FY2026, with $6.5M in award dollars. Counts include each project's later non-competing years, which keep the original NOFO number.
Projects funded
3
Distinct projects, FY2022–FY2026
New awards
3
Type 1 (new project) award records
NIH funding
$6.5M
Award dollars under PAR-25-296, FY2022–FY2026
Funding by fiscal year
| Fiscal year | Award records | New awards | Funding |
|---|---|---|---|
| FY2022 | 0 | 0 | $0 |
| FY2023 | 0 | 0 | $0 |
| FY2024 | 0 | 0 | $0 |
| FY2025 | 0 | 0 | $0 |
| FY2026 | 3 | 3 | $6.5M |
Institutions with the most funding
- Boston Children's Hospital$3.4M · 1 project
- Weill Medical Coll of Cornell Univ$2.1M · 1 project
- University of Alabama at Birmingham$1.0M · 1 project
Funding institutes
- NCATS$6.5M · 3
Activity codes funded
- UG33 records
Most recent new awards
- Advancing the development, dissemination, and sustainable implementation of evidence-based screening and treatment with trustworthy GenAI and responsible AI workforce (opens NIH RePORTER)
Weill Medical Coll of Cornell Univ · 1UG3TR005954-01A1 · NCATS · Notice Aug 25, 2026
$2.1MUG3
- Advancing Evidence-Based Dental Practice Through Collaboration and Professional Development (opens NIH RePORTER)
University of Alabama at Birmingham · 1UG3TR006250-01 · NCATS · Notice Aug 24, 2026
$1.0MUG3
- Transforming Clinical Trial Recruitment: AI-Driven Federated Clinical and Genomic Matching with GIC-Recruit (opens NIH RePORTER)
Boston Children's Hospital · 1UG3TR005955-01 · NCATS · Notice Jul 9, 2026
$3.4MUG3
What its predecessor PAR-22-167 funded
PAR-25-296 reissues PAR-22-167. Its funding history is the best guide to who wins under this program: 4 projects and $9.2M in FY2022–FY2026.
Projects funded
4
Distinct projects, FY2022–FY2026
New awards
3
Type 1 (new project) award records
NIH funding
$9.2M
Award dollars under PAR-22-167, FY2022–FY2026
Funding by fiscal year
| Fiscal year | Award records | New awards | Funding |
|---|---|---|---|
| FY2022 | 0 | 0 | $0 |
| FY2023 | 1 | 1 | $1.1M |
| FY2024 | 3 | 2 | $3.2M |
| FY2025 | 3 | 0 | $3.0M |
| FY2026 | 2 | 0 | $2.0M |
Institutions with the most funding
- State University of New York at Buffalo$3.1M · 2 projects
- University of Illinois at Chicago$3.1M · 1 project
- Wake Forest University Health Sciences$2.9M · 1 project
Funding institutes
- NCATS$9.2M · 9
Activity codes funded
- UG38 records
- UH31 record
Most recent new awards
- Improving Efficiency, Quality, and Equity: Randomized Controlled Evaluations of Remote vs. In-Person Clinical Trial Methods (opens NIH RePORTER)
State University of New York at Buffalo · 1UG3TR004797-01A1 · NCATS · Notice Jul 25, 2024
$1.1MUG3
- Bytes to Bedside: Collaborative Development for Translational Clinical Decision Support (opens NIH RePORTER)
Wake Forest University Health Sciences · 1UG3TR004803-01 · NCATS · Notice Jan 12, 2024
$1.0MUG3
- Integration and interoperability of complex data and tissues from the human brain (opens NIH RePORTER)
University of Illinois at Chicago · 1UG3TR004501-01A1 · NCATS · Notice Sep 20, 2023
$1.1MUG3
FY2026 closed on September 30, 2026, but NIH keeps posting that year's awards to RePORTER for several weeks. FY2026 figures reflect records available on October 16, 2026 and may rise slightly at the next refresh.
Participating institutes
11 NIH institutes and offices take applications under PAR-25-296. Contact the program officer at the institute that fits your research before applying.
- NCATS · National Center for Advancing Translational Sciences
- NHGRI · National Human Genome Research Institute
- NIAID · National Institute of Allergy and Infectious Diseases
- NIAMS · National Institute of Arthritis and Musculoskeletal and Skin Diseases
- NICHD · Eunice Kennedy Shriver National Institute of Child Health and Human Development
- NIDCR · National Institute of Dental and Craniofacial Research
- NIGMS · National Institute of General Medical Sciences
- ODP
- OBSSR
- ORWH
- NIMHD · National Institute on Minority Health and Health Disparities
Related notices
Mar 31, 2025
This funding opportunity was updated to align with agency priorities. Carefully reread the full funding opportunity and make any needed adjustments to your application prior to submission.
Dec 12, 2024 · NOT-TR-25-004
Notice of Information: Technical Assistance Webinar for PAR-25-296: Limited Competition: Clinical and Translational Science Award CTSA) Program: Collaborative and Innovative Acceleration Award UG3/UH3 Clinical Trial Optional) . See Notice NOT-TR-25-004.April 4, 2024 - Overview of Grant…
Aug 31, 2022 · NOT-OD-22-198
Implementation Changes for Genomic Data Sharing Plans Included with Applications Due on or after January 25, 2023. See Notice NOT-OD-22-198.
Aug 5, 2022 · NOT-OD-22-189
Implementation Details for the NIH Data Management and Sharing Policy. See Notice NOT-OD-22-189.
Award terms
- Application types allowed
- NewResubmission - Resubmission applications to PAR-22-167 and this NOFO The OER Glossary and the How to Apply Application Guide provide details on these application types. Only those application types listed here are allowed for this NOFO.
- Award budget
- Application budgets need to reflect the actual needs of the proposed project.Direct cost funding support may not exceed 650,000 per year for the UG3 Phase of awards and 650,000 per year for the UH3 Phase awards.
- Project period
- The scope of the proposed project should determine the project period.The project period may be up to 1- 3 years for the UG3 phase.The project period may be up to 2 - 4 years for the UH3 phase.The maximum project period for the entire UG3/UH3 award is 5 years. NIH grants policies as described in the NIH Grants Policy Statement will apply to the applications submitted and awards made from this…
- Funds available and number of awards
- NCATS intends to commit up to 5 million per Fiscal Year for the CCIA Awards.The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications
Summarized from the NOFO text; the full NOFO governs eligibility, budget, and review.
Related NOFOs
- Reissue of PAR-22-167.
Other open NOFOs for UG3, UH3
- PAR-27-015Community-Based Participatory Research to Advance Data and Practice Transformation (ADAPT) for Optimizing Oral Health for All (UG3/UH3 Clinical Trial Optional)NIDCR · next due Oct 16, 2026
- RFA-RM-27-012PRIMED-AI: Data-to-Model Academic-Industrial Partnerships (D2M-AIP) for Precision Medicine with AI: Integrating Imaging with Multimodal Data (UG3/UH3 Clinical Trial Optional)RMOD · next due Oct 19, 2026
- RFA-RM-27-013Model-to-Clinic (M2C) for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (UG3/UH3, Clinical Trial Optional)RMOD · next due Oct 19, 2026
- PAR-25-226Seamless Early-Stage Clinical Drug Development (Phase 1 to 2a) for Novel therapeutic Agents for the Spectrum of Alzheimer's Disease (AD) and AD-related Dementias (ADRD) (UG3/UH3 Clinical Trial Required)NIA · next due Oct 19, 2026
- PAR-25-052NIH StrokeNet Clinical Trials and Biomarker Studies for Stroke Treatment, Recovery, and Prevention (UG3/UH3 Clinical Trial Optional)NINDS · next due Oct 19, 2026
- PAR-25-446Development of Interventions to Prevent and Treat Substance Use Disorders and Overdose (UG3/UH3 - Clinical Trial Optional)NIDA · next due Oct 20, 2026
About this page
GotGrant gathers the NOFO, its participation and change notices, and its NOSIs from the NIH Guide for Grants and Contracts, and counts funded projects from NIH RePORTER by the opportunity number each award was made under. Data refreshed October 16, 2026; the NIH Guide is the authoritative source. See our data methodology.